GraftWorx Smart Vascular Prosthetics Named Best in Show at Angel Investor Event


June 9, 2015—Mid-Atlantic Bio Angels (MABA) announced that GraftWorx was chosen as “Best in Show” at MABA's 1st Pitch Life Science event, which took place at the New York Genomics Center on June 3, 2015. GraftWorx is a medical device company that has developed a vascular prosthetic incorporating a sensor that can alert physicians when blood flow is blocked to dangerous levels in patients with peripheral artery disease. David J. Kuraguntla is Founder and Chief Executive Officer of GraftWorx.

The device was developed to address the problem of implantable prosthetic devices for treating peripheral artery disease that become blocked, leading to expensive, debilitating outcomes if it goes undetected.

According to MABA, GraftWorx solves this problem with its “smart” vascular prosthetics with a built-in sensor that can detect and accurately measure restenosis formation and progress, along with monitoring other hemodynamic parameters in patients. Well before the prosthetic has reached failure, the device should automatically alert clinicians so that they can bring in the patient for a simple, safe, outpatient angioplasty procedure. This allows both the clinicians and patients to avoid the catastrophic results of undetected prosthetic failure, such as an amputation or prosthetic replacement.

MABA is a group of investors with significant expertise and experience in the biotechnology, pharmaceutical, and health care industries. The group meets in New York City monthly (except July and August), solely to hear from prescreened, early-stage, life science companies. MABA’s goal is to create an environment in which the depth of investors’ knowledge coupled with the prescreening of presenting companies enhances the potential for meaningful investment.

At a 1st Pitch event, early-stage life sciences and health care companies make a 15-minute presentation to a panel of experienced life science investors and consultants, followed by a 15-minute audience question and answer session. However, where actual investors would then ask the presenting company to leave the room during their subsequent discussion, presenting companies at 1st Pitch are invited to hear the panel constructively critique the company's presentation, business model, and perceived viability in the market.


Contact Info

For advertising rates and opportunities, contact:
Craig McChesney

Stephen Hoerst

Charles Philip

About Endovascular Today

Endovascular Today is a publication dedicated to bringing you comprehensive coverage of all the latest technology, techniques, and developments in the endovascular field. Our Editorial Advisory Board is composed of the top endovascular specialists, including interventional cardiologists, interventional radiologists, vascular surgeons, neurologists, and vascular medicine practitioners, and our publication is read by an audience of more than 22,000 members of the endovascular community.